Tetraphase Pharmaceutical

(NASDAQ: TTPH)
Healthcare  |  Biotechnology
4.69 -0.38 -7.5%
Stock Price | Oct. 18, 2019, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 5.07
52 Week Low: 3.3559
52 Week High: 49.596
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is XERAVA (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 10/29/2015

3 years ago

Premium Stock Watchlist 10/28/2015

3 years ago
4 years ago
4 years ago

Premium Daily Trade Recommendations | WEN - MOH

4 years ago
4 years ago